Home > Publications Database > Oxytocin enhances attractiveness of unfamiliar female faces independent of the dopamine reward system. > print

001     137252
005     20240321220221.0
024 7 _ |a 10.1016/j.psyneuen.2013.09.026
|2 doi
024 7 _ |a pmid:24275006
|2 pmid
024 7 _ |a 0306-4530
|2 ISSN
024 7 _ |a 1873-3360
|2 ISSN
024 7 _ |a altmetric:1842281
|2 altmetric
037 _ _ |a DZNE-2020-03574
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Striepens, Nadine
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Oxytocin enhances attractiveness of unfamiliar female faces independent of the dopamine reward system.
260 _ _ |a Amsterdam [u.a.]
|c 2014
|b Elsevier Science
264 _ 1 |3 print
|2 Crossref
|b Elsevier BV
|c 2014-01-01
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1705997990_18608
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Evidence from animal studies suggests that the social attraction and bonding effects of the neuropeptide oxytocin (OXT) are mediated by its modulation of dopamine (DA) release in brain reward centers, but this has not yet been demonstrated in humans. DA release can be measured by positron emission tomography (PET) using the radioligand [11C]raclopride. Its binding to DA D2 receptors (D2R) is sensitive and reciprocally related to endogenous DA, especially in the striatum. In a randomized double-blind placebo-controlled within-subjects trial on 18 adult male volunteers we combined [11C]raclopride PET and a facial attractiveness rating task to establish whether intranasal OXT (24 IU) increased both the perceived attractiveness of unfamiliar female faces and striatal DA release compared with placebo administration. While our behavioral data confirmed that subjects rated unfamiliar female faces as more attractive following OXT treatment, and this correlated with an increased perfusion rate in the striatum, there was no evidence for altered [11C]raclopride binding in the striatum or pallidum. Instead under OXT we rather observed an increased [11C]raclopride binding and reduced perfusion rate in subregions of the right dorsomedial prefrontal gyrus and superior parietal gyrus. The absence of OXT effects on dopamine release and D2 receptors in brain reward centers, despite increased striatal activity, implies that the peptide may facilitate perceived attraction via non-dopaminergic actions.
536 _ _ |a 344 - Clinical and Health Care Research (POF3-344)
|0 G:(DE-HGF)POF3-344
|c POF3-344
|f POF III
|x 0
542 _ _ |i 2014-01-01
|2 Crossref
|u https://www.elsevier.com/tdm/userlicense/1.0/
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Raclopride
|0 430K3SOZ7G
|2 NLM Chemicals
650 _ 7 |a Oxytocin
|0 50-56-6
|2 NLM Chemicals
650 _ 7 |a Dopamine
|0 VTD58H1Z2X
|2 NLM Chemicals
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Corpus Striatum: diagnostic imaging
|2 MeSH
650 _ 2 |a Corpus Striatum: drug effects
|2 MeSH
650 _ 2 |a Corpus Striatum: metabolism
|2 MeSH
650 _ 2 |a Dopamine: metabolism
|2 MeSH
650 _ 2 |a Double-Blind Method
|2 MeSH
650 _ 2 |a Face
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Oxytocin: pharmacology
|2 MeSH
650 _ 2 |a Raclopride: pharmacology
|2 MeSH
650 _ 2 |a Radionuclide Imaging
|2 MeSH
700 1 _ |a Matusch, Andreas
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Kendrick, Keith M
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Mihov, Yoan
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Elmenhorst, David
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Becker, Benjamin
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Lang, Markus
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Coenen, Heinz H
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Maier, Wolfgang
|0 P:(DE-2719)2000015
|b 8
|u dzne
700 1 _ |a Hurlemann, René
|0 P:(DE-HGF)0
|b 9
|e Corresponding author
700 1 _ |a Bauer, Andreas
|0 P:(DE-HGF)0
|b 10
773 1 8 |a 10.1016/j.psyneuen.2013.09.026
|b : Elsevier BV, 2014-01-01
|p 74-87
|3 journal-article
|2 Crossref
|t Psychoneuroendocrinology
|v 39
|y 2014
|x 0306-4530
773 _ _ |a 10.1016/j.psyneuen.2013.09.026
|g Vol. 39, p. 74 - 87
|0 PERI:(DE-600)1500706-6
|q 39<74 - 87
|p 74-87
|t Psychoneuroendocrinology
|v 39
|y 2014
|x 0306-4530
856 4 _ |u https://pub.dzne.de/record/137252/files/DZNE-2020-03574_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/137252/files/DZNE-2020-03574_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:pub.dzne.de:137252
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2000015
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-344
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2014
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b PSYCHONEUROENDOCRINO : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-2719)7000001
|k U Clinical Researchers - Bonn
|l U Clinical Researchers - Bonn
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)7000001
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21